# Melior Discovery

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/melior-discovery

- Industry: Pharmaceuticals
- Headquarters: Exton, US
- Website: www.meliordiscovery.com
- Total disclosed funding: $5M
- Latest round: Series B (Sep 10, 2009)
- Investors on record: 3

## About

Melior Discovery Inc. is a company specializing in pharmacology services, providing preclinical efficacy data through validated animal models to support drug development for pharmaceutical and biotechnology clients.Founded in 2005 and headquartered in Exton, US, Melior Discovery Inc. focuses on preclinical pharmacology services, generating efficacy data with over 150 validated animal models primarily using rats and mice. The company has completed 7 deals as of June 24, 2020, when it raised USD 1.740 mn in a Series A funding round. Andrew Reaume is the CEO, overseeing the company's operations and strategy.Melior Discovery specializes in in vivo pharmacology services, focusing on preclinical efficacy data generation through validated animal models for drug development. The company's extensive catalog includes over 150 validated models, primarily using rats and mice, covering 14 therapeutic areas. Their offerings include not only standard models but also customized modifications, catering to the unique needs of pharmaceutical and biotechnology clients. Melior's proprietary platforms, thera TRACE® and opioid TRACE®, assist clients in drug repositioning, repurposing, and discovering new therapeutic indications. The company primarily serves clients in North America and Europe, partnering with pharmaceutical companies and research institutions requiring sophisticated solutions for drug discovery and development.Melior Discovery operates on a transactional model involving direct partnerships with pharmaceutical and biotechnology firms, providing tailored preclinical services. Clients can access various service options, potentially structured around project-based pricing or ongoing contracts for long-term studies, particularly utilizing their thera TRACE® and opioid TRACE® platforms. Services are priced based on the complexity and duration of the studies conducted, allowing clients to scale their investment according to project needs. Engagements typically include a combination of one-time project fees and possible subscription models for ongoing access to services and expertise, establishing a consistent revenue stream aligned with client research timelines and requirements.In June 2020, Melior Discovery Inc. received an undisclosed amount of grant funding from new investor SFA. This funding is expected to support the company's strategy for future growth, which includes the development of new products and possibly expanding their presence in the North American and European markets.

## Funding rounds

- Series B, Sep 10, 2009, $0.8M — Osage Venture Partners
- Series A, Jan 31, 2006, $3.7M — Ventureast, Osage Venture Partners
- Seed, Jan 25, 2005, $0.5M — BioAdvance

## Investors

- BioAdvance (https://capitalatlas.ai/funds/bioadvance) — Seed
- Ventureast (https://capitalatlas.ai/funds/ventureast) — Series A
- Osage Venture Partners (https://capitalatlas.ai/funds/osage-venture-partners) — Series A, Series B